Sarcoma  >>  benmelstobart (APL-502)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
benmelstobart (APL-502) / Apollomics
TQB2450-Ib-02, CTR20190938: TQB2450 clinical study in combination with anlotinib in the treatment of soft tissue sarcoma

Ongoing
1b
30
China
benmelstobart (APL-502) - Apollomics, Focus V (anlotinib) - Advenchen, Sino Biopharm
Nanjing Shunxin Pharmaceutical Co., Ltd./ Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Advanced soft tissue sarcoma
 
 

Download Options